Ionis Pharmaceuticals
Business Services · California, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
2855 Gazelle Ct, Carlsbad, California, 9...Phone Number
(760) 931-9200Website
www.ionis.comRevenue
$1.1 BillionStock Symbol
IONSIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
6
5
2
7
2
2
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. is a pioneering commercial-stage biotechnology company specializing in the discovery and development of RNA-targeted medicines, headquartered in Carlsbad, California. Founded in 1989 by Stanley Crooke as ISIS Pharmaceuticals and renamed Ionis in December 2015, the publicly traded company has established itself as an industry leader in antisense therapy technology, as well as RNA interference and CRISPR therapeutics. Ionis focuses on developing innovative treatments for serious diseases including cardiovascular, metabolic, neurological, and rare genetic conditions, as well as cancer. The company's proprietary antisense technology platform enables the discovery of first-in-class and best-in-class medicines that target RNA to modulate protein production.Explore more
Ionis Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
BS
Vice President, Investor Relations
EK
Vice President, Accounting
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ionis Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if Ionis Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Ionis Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Ionis Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Ionis Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Ionis Pharmaceuticals recently announced quarterly report
Check out if Ionis Pharmaceuticals is spiking on competitors!
Funding: Get notified immidiatlly once Ionis Pharmaceuticals has new funding data
Product Launch: Get notified when Ionis Pharmaceuticals launches new products
Recommended Actions
Reach out to Masked Content who joined Ionis Pharmaceuticals as Masked Content
Find more new buyers
Compare Similar Companies to Ionis Pharmaceuticals
Compare insights from companies similar to Ionis Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$2.2B
501-1,000
Public
$2.8B
1980
FQ
Farzana QuddusPrincipal Engineer & Chief Marketing Officer, Operation
Company Profile Activity
Activity Insights
Ionis Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ionis Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ionis Pharmaceuticals.
Ionis Pharmaceuticals financials insights
Gather financial insights about Ionis Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Debt
$201.3M
Ionis Pharmaceuticals Tech Stack
A closer look at the technologies used by Ionis Pharmaceuticals
Most Recent Scoops
Open Position
Person-Based
Events
Open Position
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Ionis Pharmaceuticals News & Media
Ionis secures market expansion for Tryngolza as FDA clears severe hypertriglyceridemia use
The approval of Ionis Pharmaceuticals’ Tryngolza for severe hypertriglyceridemia could spur “substantial growth” for the product, according to William Blair.Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts
Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets’ Global Healthcare Conference, with Chief Development Officer Holly Kordasiewicz saying the company is moving from recent launchWhy Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106
Ionis Pharmaceuticals (NASDAQ:IONS) has delivered a remarkable 137.52% gain over the past year, though the stock has pulled back 6.12% year-to-date and sits 7.20% below its one-month high, currently trading near $72.70. The stock remains well off its 52-week high of $86.74, with the Street’s consensus target sitting at $93.90 across 22 analysts. Barclays stands ... Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ionis Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Ionis Pharmaceuticals, Inc. is a pioneering commercial-stage biotechnology company specializing in the discovery and development of RNA-targeted medicines, headquartered in Carlsbad, California. Founded in 1989 by Stanley Crooke as ISIS Pharmaceuticals and renamed Ionis in December 2015, the publicly traded company has established itself as an indu... Read More
